Search Results

You are looking at 111 - 120 of 431 items for :

  • "Adjuvant therapy" x
  • All content x
Clear All
Full access

Harold J. Burstein

, hopefully unbiased, fashion. Let’s apply this strategy to two important trials in early-stage breast cancer; the HERA study, which compared 0 versus 1 versus 2 years of trastuzumab as adjuvant therapy for HER2-positive breast cancers (the comparison of 1

Full access

David H. Moore

with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix . J Clin Oncol 2000 ; 18 : 1606 – 1613 . 27 Clinical Announcement . National Cancer Institute. Concurrent

Full access

Robert J. Downey and Lee M. Krug

-term survival after pulmonary resection for small cell carcinoma of the lung [comment] . Thorax 1989 ; 44 : 784 – 787 . 11 Shah SS Thompson J Goldstraw P . Results of operation without adjuvant therapy in the treatment of small cell lung cancer

Full access

Alyssa G. Rieber and Richard L. Theriault

. Lancet 2005 ; 365 : 60 – 62 . 16 Winer EP Hudis C Burstein HJ . American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast

Full access

Margaret Tempero

landmark studies, such as those that defined adjuvant therapy in breast and colorectal cancers, two of the biggest success stories. So my answer to the title question is “yes,” we need a publicly funded clinical trials network. The pharmaceutical industry

Full access

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell

In an era of increasing use of Oncotype DX to assist with chemotherapy treatment decisions, an aging population with comorbidities needing to be addressed, and the more prevalent use of MIR, it is not surprising that wait times to adjuvant therapy

Full access

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A. Valea, Emily Wyse, Catheryn M. Yashar, Nicole McMillian, and Jillian Scavone

has shifted from radical approaches to more conservative surgery with the addition of RT or chemoradiation. 15 Because the data are limited, trials are ongoing to identify optimal approaches for neoadjuvant and adjuvant therapy, which may include

Full access

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff

progesterone receptors in the treatment of breast cancer . Cancer 1980 ; 46 ( 12 Suppl ): 2884 – 2888 . 5 Viale G Regan MM Maiorano E . Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

complete response; TME, total mesorectal excision. Historically, one of the major shortfalls of adjuvant therapy is that many eligible patients, ranging from 17% to 28% in various trials, either do not start postoperative chemotherapy or initiate

Full access

Ali A. Mokdad, Rebecca M. Minter, Adam C. Yopp, Matthew R. Porembka, Sam C. Wang, Hong Zhu, Mathew M. Augustine, John C. Mansour, Michael A. Choti, and Patricio M. Polanco

between preoperative CT and CRT despite more favorable postoperative pathologic findings with CRT. Our results also suggest higher postoperative morbidity and mortality and lower delivery rates of postoperative adjuvant therapy associated with preoperative